Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post on X about a recent paper by Thierry André et al. published in The Lancet:
“Very intriguing to see differences of single agent PD1 vs combination with CTLA4.
I wasn’t expecting a difference in the two arms for the subset analyses.
Pleasantly surprised.
71% vs 58% differences in overall response is an important consideration too.
One thing that I didn’t notice till the Q&A is that this immunotherapy comparison of NIVO vs IPI/NIVO was not just for treatment-naive, it was for all lines of therapy.
What would be of value is the difference in 1st line patient population given pembrolizumab approval.”
Authors: Thierry André, Elena Elez, Heinz-Josef Lenz, Steven Blum, Sara Lonardi et al.
More posts featuring Pashtoon Kasi.
